Multiplex 'Conditional' Mice for Rapid and Affordable Pre-clinical Testing
Multiplex 'Conditional' Mice for Rapid and Affordable Pre-clinical Testing
批准号:
9195708
负责人:
Branden S Moriarity
金额:
$7.62万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-12-15 至 2018-03-31
关键词:
AdultAffectAllelesCRISPR/Cas technologyCancer ModelCellsChildhoodClinicClustered Regularly Interspaced Short Palindromic RepeatsComplexControl AnimalCre-LoxPDevelopmentDiseaseEnterobacteria phage P1 Cre recombinaseEvaluationGene Expression ProfilingGene TargetingGene Transfer TechniquesGenerationsGenesGenetic RecombinationGuide RNAHistologicIndividualInjection of therapeutic agentLoxP-flanked alleleMalignant neoplasm of pancreasMethodsModelingMolecular BiologyMolecular ProfilingMusMutationNeoplasm MetastasisOncogenesPatientsPhenotypePlasmidsPre-Clinical ModelReactionResearchResearch PersonnelResourcesRibonucleasesSafetySiteSomatic CellSystemTechnologyTestingTimeTissuesTransgenesTransgenic MiceTransgenic OrganismsTumor Suppressor GenesTumor-DerivedWestern Blottingagedanticancer researchbasecancer therapycostcost effectivedrug testingembryonic stem cellhomologous recombinationimprovedmouse genomemouse modelnew technologynovel therapeuticsnucleaseosteosarcomaplasmid DNApre-clinicalprogramspromoterpublic health relevancerepairedresearch clinical testingrestriction enzymetumortumor progressiontumorigenesisvector
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Mouse models of cancer have proven to be highly effective pre-clinical models for testing new cancer therapies for safety and efficacy. However, the generation of the most applicable mouse models of cancer is costly, time-consuming, and therefore not widely implemented. Generating new mouse models of cancer utilizing recently developed cutting-edge technologies will produce superior models in a more affordable and rapid fashion allowing new therapies to reach the clinic in a timely manner. To this end, we will optimize and implement a newly developed technology termed the CRISPR system. This system allows researchers to specifically delete or modify multiple portions of the mouse genome at one time in specific cells to induce tumor development. This model of cancer development as a pre- clinical testing platform is superior to current models as it is more rapid, cost effective, and easy to use. This will allow pre-clinical testing in accurate mouse models of cancer to be performed by many labs that do not have the resources to utilize the current mouse models, due to the aforementioned drawbacks. We propose to use the CRISPR system to generate new models of rapid onset osteosarcoma and pancreatic cancer, devastating diseases that affect pediatric and adult patients, respectively. All of the advantages of the CRISPR based models over traditional models will certainly attract many research labs to capitalize on the technologies potential in the field of cancer research and other diseases.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1371/journal.pone.0198714
发表时间:
2018
期刊:
PloS one
影响因子:
3.7
作者:
[Kurata M, Wolf NK, Lahr WS, Weg MT, Kluesner MG, Lee S, Hui K, Shiraiwa M, Webber BR, Moriarity BS]
通讯作者:
Moriarity BS
Activated NK CAR Cells to Cure HIV
-
批准号:10382350
-
项目类别:
-
资助金额:$75.35万
-
财政年份:2021
-
负责人:Branden S Moriarity
-
依托单位:
Activated NK CAR Cells to Cure HIV
-
批准号:10584560
-
项目类别:
-
资助金额:$75.35万
-
财政年份:2021
-
负责人:Branden S Moriarity
-
依托单位:
Project 3
-
批准号:10700941
-
项目类别:
-
资助金额:$53.91万
-
财政年份:2021
-
负责人:Branden S Moriarity
-
依托单位:
Project 3
-
批准号:10270395
-
项目类别:
-
资助金额:$54.86万
-
财政年份:2021
-
负责人:Branden S Moriarity
-
依托单位:
Engineered B Cells as a Universal Platform for the Treatment of Enzymopathies
-
批准号:10582595
-
项目类别:
-
资助金额:$38.75万
-
财政年份:2020
-
负责人:Branden S Moriarity
-
依托单位:
Engineered B Cells as a Universal Platform for the Treatment of Enzymopathies
-
批准号:10358566
-
项目类别:
-
资助金额:$38.75万
-
财政年份:2020
-
负责人:Branden S Moriarity
-
依托单位:
Optimizing Gene Editing in Primary Human B Cells for Therapy and Research
-
批准号:9224508
-
项目类别:
-
资助金额:$22.88万
-
财政年份:2017
-
负责人:Branden S Moriarity
-
依托单位:
Project 4 Treatment of Advanced Ovarian Cancer Using Gene-Edited NK CAR Cells
-
批准号:10452722
-
项目类别:
-
资助金额:$24.71万
-
财政年份:2009
-
负责人:Branden S Moriarity
-
依托单位:
Project 4 Treatment of Advanced Ovarian Cancer Using Gene-Edited NK CAR Cells
-
批准号:10268766
-
项目类别:
-
资助金额:$26.27万
-
财政年份:2009
-
负责人:Branden S Moriarity
-
依托单位:
Project 4 Treatment of Advanced Ovarian Cancer Using Gene-Edited NK CAR Cells
-
批准号:10705051
-
项目类别:
-
资助金额:$23.24万
-
财政年份:2009
-
负责人:Branden S Moriarity
-
依托单位:
海外基金